<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005455</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI305K101</org_study_id>
    <nct_id>NCT05005455</nct_id>
  </id_info>
  <brief_title>Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Controlled, Single-dose Phase I Clinical Study to Evaluate Pharmacokinetic Similarity, Safety, and Immunogenicity of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic similarity of bevacizumab with&#xD;
      different manufacturing process in healthy male subjects. Another purpose is to determine&#xD;
      safety, and immunogenicity of bevacizumab with different manufacturing process.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">January 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure:Area Under the Curve(AUC0-∞)</measure>
    <time_frame>85days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve(AUClast)</measure>
    <time_frame>85days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>85days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (V)</measure>
    <time_frame>85days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CL)</measure>
    <time_frame>85days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>85days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum concentration occurred (Tmax)</measure>
    <time_frame>99days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incicende of Adverse Events (AEs)</measure>
    <time_frame>99days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>bevacizumab with old manufacturing process.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab with new manufacturing process.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab with new manufacturing process.</intervention_name>
    <description>3mg/kg,I.V.,single dose</description>
    <arm_group_label>bevacizumab with new manufacturing process.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab with old manufacturing process.</intervention_name>
    <description>3mg/kg,I.V.,single dose</description>
    <arm_group_label>bevacizumab with old manufacturing process.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign the informed consent form and fully understand the test content, process and&#xD;
             possible adverse reactions, and be able to complete the study according to the test&#xD;
             plan requirements;&#xD;
&#xD;
          -  Age≥18 years and ≤50 years, healthy male subjects;&#xD;
&#xD;
          -  Weight ≥ 50kg and ≤ 100kg,BMI≥ 19kg/m2 and &lt; 28 kg/m2&#xD;
&#xD;
          -  Clinical examinations in the screening period are normal or abnormal without clinical&#xD;
             significance.&#xD;
&#xD;
          -  Agree to take effective contraceptive measures throughout the study period and until&#xD;
             at least 6 months after receiving the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior VEGF(vascular endothelial growth factor) and VEGFR(Vascular Endothelial&#xD;
             Growth Factor Receptor) antibody or protein treatment within one year.&#xD;
&#xD;
          2. Serious, non-healing wound, active ulcer, or untreated bone fracture, or major&#xD;
             surgical procedure within 2 months prior to randomization or anticipation of need for&#xD;
             major surgery during the course of the study or 2 months after end of the study.&#xD;
&#xD;
          3. Use Rx or OTC drugs or nutritional health products within 5 half-lives or within 2&#xD;
             weeks before the first dose of study drug (According to the longer time).Herbal&#xD;
             supplements need to stop at 28 days before the first dose of study drug.&#xD;
&#xD;
          4. Positive hepatitis b surface antigen (HBsAg), hepatitis c virus (HCV) antibody, or&#xD;
             human immunodeficiency virus (HIV) antibody or syphilis.&#xD;
&#xD;
          5. Known hypersensitivity to bevacizumab or any excipients, known allergic disease or&#xD;
             allergic constitution.&#xD;
&#xD;
          6. History of blood donation within 3 months before the first dose of study drug.&#xD;
&#xD;
          7. Treatment with any other investigational agent or participation in another clinical&#xD;
             trial within 3 months prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Age≥18 years and ≤50 years, healthy male subjects</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Bai, Master</last_name>
    <phone>18201333260</phone>
    <email>li.bai@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first affiliated hospital of Soochow university</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liyan Miao, Doctor</last_name>
      <phone>18915505252</phone>
      <email>sdyff8040@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

